SA’s biggest pharmaceutical manufacturer Aspen Pharmacare says it is on track to meet its debt reduction targets by the end of its financial year, after agreeing to sell its Japanese business to Novartis’s generic division Sandoz for as much as €400m (R6.5bn).

It has also entered into a five-year manufacturing and supply agreement with Sandoz for the portfolio of divested brands.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now